Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Clinical studies with Strangvac have begun in the U.S. market
Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac® in the U.S. The initial phase of the safety studies, involving vaccination of horses in...Interim report January – September 2025
The Group in summary 01/07/25 01/07/24 01/01/25 01/01/24 Full year -30/09/25 -30/09/24 -30/09/25 -30/09/24 2024 Net sales 5 378 2 531 16 964 7 660 11 787 Operating result...Delårsrapport januari – september 2025
Koncernen i sammandrag 2025-07-01 2024-07-01 2025-01-01 2024-01-01 Helår -2025-09-30 -2024-09-30 -2025-09-30 -2025-09-30 2024 Nettoomsättning 5 378 2 531 16 964 7 660 11 787 Rörelseresultat -14 976 -22 514 -47 124 -58 772 -77 277 Resultat efter finansiella poster -14...Intervacc and Dechra extend distribution agreement for Intervacc’s equine strangles vaccine Strangvac by two years
Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will take effect in April 2026. The agreement covers Strangvac®, Intervacc’s...Intervacc appoints Anna-Carin Lagerlöf as Sales and Marketing Director
The animal health group Intervacc AB (publ) has appointed Anna-Carin Lagerlöf to the newly established role as Sales and Marketing Director. In this position, Anna-Carin will lead the company’s continued sales growth, with a particular focus on Strangvac® –...Nyhetstjänster
